natgillin/translations-raw huggingface dataset:
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
• široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Poleg tega delno preprečuje inhibicijo GABA in glicinskih kanalov, povzročeno z Zn2+ in β- karbolini.
- The active substance is levetiracetam.
- Učinkovina je levetiracetam.
In all of the above cases an oral solution should be used.
V vseh zgoraj naštetih primerih se priporoča uporaba peroralne raztopine.
In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
Delež bolnikov iz zbranih analiz, pri katerih je bilo doseženo 50- ali več odstotno zmanjšanje pogostnosti napadov parcialnega izvora na teden pri stalnem odmerku (12/14 tednov), je bil 27,7 % pri bolnikih, ki so prejemali 1000 mg, 31,6 % pri bolnikih, ki so prejemali 2000 mg in 41,3 % pri bolnikih, ki so prejemali 3000 mg levetiracetama, ter 12,6 % pri bolnikih, ki so prejemali placebo.
If you take more Levetiracetam Teva than you should
Če ste vzeli večji odmerek zdravila Levetiracetam Teva, kot bi smeli
Very common: may affect more than 1 in 10 people
Zelo pogosti: pojavijo se pri več kot 1 od 10 oseb
20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 50x1 film-coated tablet 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets
20 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 50x1 filmsko obložena tableta 60 filmsko obloženih tablet 100 flmsko obloženih tablet 120 filmsko obloženih tablet 200 filmsko obloženih tablet
The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies.
Odmerki 1800 mg/kg/dan so sprožili izrazito toksičnost pri samicah in zmanjšanje telesne mase zarodka, povezano s povečanjem pogostnosti zarodkov s kardiovaskularnimi/skeletnimi anomalijami.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day.
Dve študiji embriofetalnega razvoja pri podganah so izvedli z odmerki 400, 1200 in 3600 mg/kg/dan.
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
• gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg.
Prav tako jakosti tablet, ki so na voljo, niso primerne za doseganje začetnega odmerka pri otrocih, ki so težki do 25 kg, za uporabo pri bolnikih, ki ne morejo pogoltniti tablet ali za dajanje odmerkov nižjih od 250 mg.
Other medicines and Levetiracetam Teva
Druga zdravila in zdravilo Levetiacetam Teva
It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Ugotovili so, da se levetiracetam pri populaciji po protokolu ne razlikuje (ni manjvredno) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
Contents of the pack and other information What Levetiracetam Teva contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Levetiracetam Teva
However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products.
Vendar pa podatki nakazujejo, da je pri otrocih, ki jemljejo protiepileptična zdravila, ki inducirajo encime, povečan očistek levetiracetama za 20 %.
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.
Zdravnik mora glede na starost, telesno maso in odmerek predpisati najustrežnejšo farmacevtsko obliko, velikost pakiranja in jakost.
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).
Pri odraslih in otrocih so ugotovili pomembno povezavo med koncentracijo v plazmi in slini (razmerje koncentracij v slini/plazmi se giblje med 1 in 1,7 za tableto za peroralno uporabo in za peroralno raztopino 4 ure po odmerku).
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Levetiracetam in sorodni analogi kažejo vrstni red afinitete za vezavo na sinaptični vezikularni protein 2A, ki korelira z jakostjo protiepileptične zaščite pri mišjem audiogenem modelu epilepsije.
• a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
• kožni izpuščaj, ki lahko tvori mehurčke in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem)
*The colourants are: 250 mg film-coated tablets: brilliant blue FCF (E133) and indigotine (E132).
*Barvila so: 250 mg filmsko obložene tablete: briljantno modro FCF (E133) in indigotin (E132).
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
• šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks).
pri odraslih in mladostnikih, težkih več kot 50 kg: zmanjševanje odmerka za 500 mg dvakrat na dan na vsaka dva tedna do štiri tedne; pri dojenčkih, starejših od 6 mesecev, otrocih in mladostnikih s telesno maso manj kot 50 kg: zmanjšanje odmerka ne sme preseči 10 mg/kg dvakrat na dan vsaka dva tedna; pri dojenčkih (mlajših od 6 mesecev): zmanjšanje odmerka ne sme preseči 7 mg/kg dvakrat na dan vsaka dva tedna).
• decreased number of blood platelets, decreased number of white blood cells;
• zmanjšano število krvnih ploščic, zmanjšano število belih krvnih celic • zmanjšanje telesne mase, povečanje telesne mase
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study.
Poleg tega je bilo v študijo o varnosti v obdobju po začetku trženja zdravila vključenih 101 dojenčkov, mlajših od 12 mesecev.
Transparent PVC/PVdC - aluminium blisters.
Prozorni pretisni omot iz PVC/PVdC-aluminija.
• Levetiracetam Teva is used as a chronic treatment.
• Zdravilo Levetiracetam Teva se uporablja za dolgotrajno zdravljenje.
• Levetiracetam Teva is not indicated in children and adolescents below 16 years on its own (monotherapy).
• Zdravilo Levetiracetam Teva pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
The maximum dose is 1500 mg twice daily.
Največji odmerek je 1500 mg dvakrat na dan.
• Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:
• Odmerjanje pri dojenčkih (od 1 meseca do 23 mesecev), otrocih (od 2 do 11 let) in mladostnikih (od 12 do 17 let), lažjih od 50 kg:
Each Levetiracetam Teva 250, 500, 750, 1,000 mg film-coated tablet contains 250, 500, 750, 1,000 mg levetiracetam.
Ena 250, 500, 750, 1.000 mg filmsko obložena tableta zdravila Levetiracetam Teva vsebuje 250, 500, 750, 1.000 mg levetiracetama.
The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.
Frakcijska odstranitev levetiracetama med tipično 4-urno dializo je bila 51 %.
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Farmacevtska oblika tableta ni primerna za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
If stopping treatment, Levetiracetam Teva should be discontinued gradually to avoid an increase of seizures.
Pri zdravilu Levetiracetam Teva je treba zdravljenje opustiti postopoma, da se število napadov ne bi povečalo.
• as an add-on to other antiepileptic medicines to treat: ■ partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age ■ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ■ primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
■ parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca dalje ■ miokloničnih napadov (kratki, nenadni trzaji mišice ali skupine mišic) pri odraslih in mladostnikih od 12. leta starosti z juvenilno mioklonično epilepsijo ■ primarno generaliziranih tonično-kloničnih napadov (veliki napadi, vključno z izgubo zavesti) pri odraslih in mladostnikih od 12. leta starosti z idiopatsko generalizirano epilepsijo (oblika epilepsije, za katero se domneva, da je genetskega izvora)
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
Tako kot pri odraslih tudi pri pediatričnih bolnikih, ki so prejemali do 60 mg/kg/dan levetiracetama, ni jasnih dokazov o klinično značilnem medsebojnem delovanju z zdravili.
In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.
V tej študiji je bil odmerek levetiracetama za odrasle in mladostnike 3.000 mg na dan, za otroke pa 60 mg/kg/dan, razdeljen na dva odmerka.
Therefore, there is no need for plasma level monitoring of levetiracetam.
Koncentracije levetiracetama v plazmi zato ni treba kontrolirati.
If you stop taking Levetiracetam Teva
Če ste prenehali jemati zdravilo Levetiracetam Teva
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Učinkovitost levetiracetama je bila dokazana v 24-tedenski dvojno slepi, s placebom nadzorovani študiji, ki je vključevala odrasle, mladostnike in omejeno število otrok z idiopatsko generalizirano epilepsijo s primarno generaliziranimi tonično-kloničnimi (PGTC) napadi pri različnih sindromih (juvenilna mioklonična epilepsija, juvenilna epilepsija z absencami, otroška epilepsija z absencami ali epilepsija z grand mal napadi pri prebujanju).
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities.
In vitro so pokazali, da levetiracetam in njegov primarni presnovek ne zavirata aktivnosti glavnih izooblik človeškega jetrnega citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 in 1A2),
CLcr (ml/min/1.73 m2) = CLcr (ml/min)__ x 1.73
CLcr (ml/min/1,73 m2) = CLcr (ml/min) x 1,73 BSA bolnika (m2)
For adult patients, refer to the following table and adjust the dose as indicated.
Sklicujoč se na spodnjo preglednico se odmerek za odrasle bolnike prilagodi kot je navedeno.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function.
Pri otrocih z ledvično okvaro je treba odmerek levetiracetama prilagoditi glede na delovanje ledvic,
The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.
Tako levetiracetam kot njegov primarni presnovek se ne vežeta pomembno na beljakovine v plazmi Volumen porazdelitve levetiracetama je približno 0,5 do 0,7 l/kg, kar je blizu vrednosti celotnega volumna vode v telesu.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje, da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
Infection
• okužba
(4)Following dialysis, a 3.5 to 7 mg/kg supplemental dose is recommended.
(4)Po dializi je priporočljiv dodatni odmerek od 3,5 do 7 mg/kg.
Tablet core: maize starch, povidone, croscarmellose sodium and magnesium stearate.
Jedro tablete: koruzni škrob, povidon, premreženi natrijev karmelozat in magnezijev stearat.
The possible side effects of an overdose of Levetiracetam Teva are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju zdravila Levetiracetam Teva so zaspanost, agitiranost, agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam.
Obstajajo posamezna poročila o zmanjšani učinkovitosti levetiracetama pri sočasni uporabi makrogola, ki je osmotsko odvajalo, in peroralnega levetiracetama.
Levetiracetam Teva is used:
Zdravilo Levetiracetam Teva se uporablja:
10 to 20 mg/kg once daily (3) (5)
10 do 20 mg/kg enkrat na dan (3) (5)
Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes.
Učinkovitost levetiracetama je bila dokazana v dvojno slepi, s placebom nadzorovani 16-tedenski študiji pri bolnikih od 12 leta starosti, z idiopatsko generalizirano epilepsijo z miokloničnimi napadi pri različnih sindromih.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Štiri študije embriofetalnega razvoja pri kuncih so izvedli z odmerk 200, 600, 800, 1200 in
(5)Following dialysis, a 5 to 10 mg/kg supplemental dose is recommended.
(5)Po dializi je priporočljiv dodatni odmerek od 5 do 10 mg/kg.
Pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Velikosti pakiranj: 20, 30, 50, 60, 100, 120 in 200 filmsko obloženih tablet ter 50 x 1 filmsko obložena tableta v perforiranem pretisnem omotu iz PVC/PVdC-aluminija, za enkratni odmerek.
In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days.
Pri pediatričnih bolnikih (od 1 meseca do manj kot 4. leta starosti) je bila učinkovitost levetiracetama dokazana v dvojno slepi, s placebom nadzorovani študiji, ki je vključevala 116 bolnikov in je trajala 5
Excipient with known effect: Each film-coated tablet contains 0.35 mg colouring agent sunset yellow (E110).
Pomožna snov z znanim učinkom: Ena filmsko obložena tableta vsebuje 0,35 mg barvila oranžno FCF (E110).
500 to 1,000 mg once daily (2)
500 do 1.000 mg enkrat na dan(2)
72 x serum creatinine (mg/dl)
(x 0,85 za ženske) 72 x koncentracija kreatinina v serumu (mg/dl)
Levetiracetam Teva may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Levetiracetam Teva lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali strojev,
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50 % reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG.
Osnovno merilo učinkovitosti je bila stopnja odziva (odstotek bolnikov z ≥ 50 % znižanjem povprečnih pogostosti napadov parcialnega izvora na dan glede na začetne vrednosti), ki jo je na 48
Add-on therapy for infants aged from 1 month to less than 6 months
Dojenčki od 1 do manj kot 6 mesecev
For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
Za otroke, stare 6 let in več, se mora pri odmerkih, manjših od 250 mg, pri odmerkih, ki niso večkratniki od 250 mg in se zato priporočenega odmerjanja ne more doseči z večimi tabletami in pri bolnikih, ki ne morejo požirati tablet, uporabiti peroralno raztopino.
7 to 14 mg/kg once daily (2) (4)
7 do 14 mg/kg enkrat na dan (2) (4)
An oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Farmacevtska oblika peroralna raztopina je najprimernejša za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day.
Peri- in postnatalno študijo razvoja so izvedli pri podganah z odmerki levetiracetama po 70, 350 in
Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function:
Prilagoditev odmerjanja pri dojenčkih, otrocih in mladostnikih s telesno maso, manjšo kot 50 kg, z okvarjenim delovanjem ledvic.
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
Kumulativno se v prvih 48 urah z urinom izloči 66 % odmerka levetiracetama in 24 % odmerka njegovega primarnega presnovka.
How to take Levetiracetam Teva
Kako jemati zdravilo Levetiracetam Teva
Levetiracetam Teva are available in pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Filmsko obložene tablete zdravila Levetiracetam Teva so na voljo v pakiranjih po 20, 30, 50, 60, 100, 120 in 200 tablet ter 50 x 1 filmsko obložena tableta v perforiranem pretisnem omotu iz PVC/PVdCaluminija za enkratni odmerek.
The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily.
25 kg, mora biti 250 mg dvakrat na dan z največjim odmerkom 750 mg dvakrat na dan.
(1)An oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
(1)Pri odmerkih manjših od 250 mg, pri odmerkih, ki niso večkratniki od 250 mg in se priporočenega odmerjanja zato ne more doseči z večimi tabletami in pri bolnikih, ki ne morejo požirati tablet, je treba uporabiti peroralno raztopino.
Take the number of tablets following your doctor's instructions.
Vzemite toliko tablet, kot vam je predpisal zdravnik.
This medicinal product contains colouring agent tartrazine (E102) which may cause allergic reactions.
Zdravilo vsebuje barvilo tartrazin (E102), ki lahko povzroči alergijske reakcije.
Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Sočasna uporaba levetiracetama z digoksinom, s peroralnimi kontraceptivi in z varfarinom ni vplivala na njegovo farmakokinetiko.
What Levetiracetam Teva looks like and contents of the pack
Izgled zdravila Levetiracetam Teva in vsebina pakiranja
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]);
• hude alergijske reakcije (DRESS, anafilaktična reakcija [huda in pomembna alergijska reakcija],
The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks.
Priporočeni začetni odmerek je 250 mg dvakrat na dan, ki ga po dveh tednih povečamo na začetni terapevtski odmerek 500 mg dvakrat na dan. Odmerek se lahko poveča za 250 mg dvakrat na dan vsaka dva tedna glede na klinični odziv.
Dose and frequency
odmerjanje in pogostnost normalno delovanje ledvic
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
V tej študiji so pri dojenčkih, od 1. meseca do manj kot 6 mesecev starosti, uporabljali odmerek 20 mg/kg/dan titriran do 40 mg/kg/dan, za dojenčke in otroke, od 6 mesecev do manj kot 4. leta starosti, pa odmerek 25 mg/kg/dan titriran do 50 mg/kg/dan.
Levetiracetam Teva 500 mg contains the colouring agent tartrazine (E102) that may cause allergic reactions.
Zdravilo Levetiracetam Teva 500 mg vsebuje barvilo tartrazin (E102), ki lahko povzroči alergijske reakcije.
Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Zdravilo Levetiracetam Teva je indicirano za samostojno zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo.
Peak concentrations (Cmax) are typically 31 and 43 μg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.
Po posamičnem 1000 mg odmerku je največja koncentracija (Cmax) po navadi 31 μg/ml, po ponavljajočih odmerkih 1000 mg dvakrat na dan pa 43 μg/ml.
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam.
Probenecid Ugotovili so, da probenecid (500 mg štirikrat na dan), ki preprečuje ledvično tubularno sekrecijo,
How to store Levetiracetam Teva Contents of the pack and other information
5 Shranjevanje zdravila Levetiracetam Teva Vsebina pakiranja in dodatne informacije
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):
CLcr v ml/min/1,73 m je pri mlajših mladostnikih, otrocih in dojenčkih, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartzevi formuli): CLcr (ml/min/1,73 m2 = Višina (cm) x ks koncentracija kreatinina v serumu (mg/dl)